Fresenius Medical Care AG (NYSE:FMS) Short Interest Update

Fresenius Medical Care AG (NYSE:FMS - Get Free Report) saw a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 852,500 shares, a decline of 6.4% from the November 15th total of 910,900 shares. Based on an average daily trading volume, of 277,600 shares, the days-to-cover ratio is currently 3.1 days.

Fresenius Medical Care Trading Up 0.7 %

Shares of NYSE:FMS traded up $0.17 on Monday, hitting $23.82. The company had a trading volume of 202,283 shares, compared to its average volume of 353,660. The firm's 50-day simple moving average is $21.51 and its two-hundred day simple moving average is $20.46. The firm has a market capitalization of $13.98 billion, a price-to-earnings ratio of 19.79, a P/E/G ratio of 0.96 and a beta of 0.94. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. Fresenius Medical Care has a 1 year low of $17.93 and a 1 year high of $24.31.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Wulff Hansen & CO. increased its stake in shares of Fresenius Medical Care by 1,809.0% in the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company's stock worth $6,556,000 after acquiring an additional 325,439 shares in the last quarter. Moran Wealth Management LLC increased its stake in shares of Fresenius Medical Care by 47.0% during the third quarter. Moran Wealth Management LLC now owns 233,376 shares of the company's stock valued at $4,971,000 after purchasing an additional 74,621 shares in the last quarter. Quantinno Capital Management LP increased its stake in shares of Fresenius Medical Care by 78.9% during the third quarter. Quantinno Capital Management LP now owns 110,078 shares of the company's stock valued at $2,345,000 after purchasing an additional 48,554 shares in the last quarter. Crossmark Global Holdings Inc. lifted its holdings in shares of Fresenius Medical Care by 60.4% during the third quarter. Crossmark Global Holdings Inc. now owns 62,889 shares of the company's stock valued at $1,340,000 after purchasing an additional 23,692 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Fresenius Medical Care in the 3rd quarter worth approximately $420,000. Hedge funds and other institutional investors own 8.37% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on FMS. StockNews.com started coverage on shares of Fresenius Medical Care in a research report on Thursday, November 28th. They set a "strong-buy" rating for the company. Berenberg Bank initiated coverage on shares of Fresenius Medical Care in a report on Wednesday, November 6th. They set a "buy" rating and a $25.60 target price for the company. Bank of America upgraded Fresenius Medical Care from an "underperform" rating to a "neutral" rating in a report on Monday, December 2nd. Finally, Truist Financial increased their price objective on Fresenius Medical Care from $22.00 to $23.00 and gave the stock a "hold" rating in a report on Monday, October 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $24.30.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.